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Summary
Dietary protein enhances satiety and promotes weight loss, but the mechanisms by which appetite is affected remain
unclear. We investigated the role of gut hormones, key regulators of ingestive behavior, in mediating the satiating effects
of different macronutrients. In normal-weight and obese human subjects, high-protein intake induced the greatest release
of the anorectic hormone peptide YY (PYY) and the most pronounced satiety. Long-term augmentation of dietary protein
in mice increased plasma PYY levels, decreased food intake, and reduced adiposity. To directly determine the role of
PYY inmediating the satiating effects of protein, we generatedPyy null mice, whichwere selectively resistant to the satiating
and weight-reducing effects of protein and developed marked obesity that was reversed by exogenous PYY treatment. Our
findings suggest that modulating the release of endogenous satiety factors, such as PYY, through alteration of specific diet
constituents could provide a rational therapy for obesity.Introduction
The obesity epidemic has profound healthcare implications
(Yach et al., 2006). Body weight is regulated by complex physio-
logical mechanisms, and obesity results when there is an imbal-
ance between food intake and energy expenditure (Barsh and
Schwartz, 2002; Flier, 2004). Environmental factors interacting
with genetic susceptibility have fueled the recent rise in obesity,
with increased food availability and portion size, altered meal
composition, and lower levels of physical activity playing key
roles (Friedman, 2003; Hill and Peters, 1998). Despite significant
increases in our understanding of energy homeostasis, safe and
effective pharmacological treatments for obesity have remained
elusive (Yanovski and Yanovski, 2002). A potential therapeutic
strategy is to increase the satiating power of the diet by harness-
ing the endogenous mechanisms that suppress appetite and
caloric intake.
The average Western diet derives 49% of energy intake from
carbohydrate, 35% from fat, and 16% from protein (Henderson,
2003; USDA, 1994–1996). This differs considerably from the diet
of our hunter-gatherer ancestors who obtained 19%–35% from
protein, 28%–47% from fat, and 22%–40% from carbohydrate
(Cordain et al., 2002). This observation suggests that reduced
protein intake may be in part responsible for the high levels of
diseases of affluence in modern Western populations (Cordain
et al., 2002). Indeed, high-protein content meals have been
shown to increase satiety and decrease food intake (Latner
and Schwartz, 1999; Lejeune et al., 2006; Porrini et al., 1997),
resulting in both improved weight loss and weight loss mainte-
nance (Dumesnil et al., 2001; Skov et al., 1999; Westerterp-Plan-CELL METABOLISM 4, 223–233, SEPTEMBER 2006 ª2006 ELSEVIER INtenga et al., 2004). However, it remains unclear how increased
dietary protein increases satiety.
The gut-endocrine system plays a major role in regulating
ingestive behaviour, and a number of gut-derived hormonal sig-
nals have been characterized (Badman and Flier, 2005). Ghrelin,
a stomach-derived hormone, increases hunger and food intake.
Cholecystokinin (CCK) released from the duodenum acts as a
short-term satiety signal. Glucagon-like peptide 1 (GLP-1) and
oxyntomodulin, derived from the proglucagon gene and re-
leased from gut-endocrine L cells, decrease food intake in ro-
dents and humans (Badman and Flier, 2005). Peptide YY3-36
(PYY3-36), an agonist at neuropeptide Y2 receptors (NPY2R),
and also produced by L cells, reduces hunger and food intake
in rodents and in lean and obese humans (Batterham et al.,
2002, 2003a; Degen et al., 2005). The precise sites of action of
PYY3-36 remain to be clarified. Electrophysiological, intra-arcu-
ate administration and NPY2R antagonist studies suggest that
PYY3-36 acts directly in the hypothalamic circuits that regulate
energy homeostasis, but additional work has implicated brain-
stem and vagal inputs (Abbott et al., 2005a, 2005b; Acuna-Goy-
colea and van den Pol, 2005; Challis et al., 2003; Halatchev
and Cone, 2005; Halatchev et al., 2004). Meal-associated gut
hormone release depends on the amount and composition of
the food consumed. The satiating effects of protein require the
gut-endocrine axis, as suppression of food intake is observed
only when protein is administered enterally (Walls et al., 1991).
Gut hormones could mediate the differential satiation produced
by protein, fat, and carbohydrate. We therefore undertook
studies in normal and obese humans and mechanistic rodent
studies to investigate this hypothesis.C. DOI 10.1016/j.cmet.2006.08.001 223
A R T I C L EResults
Enhanced-protein diets cause the greatest satiation
and PYY release in humans
To determine the effect of meal macronutrient composition on
hunger scores and plasma concentrations of PYY, ghrelin, and
GLP-1, age-matched normal-weight and obese male volunteers
participated in a randomized, three-way crossover study (Table
1). Fasted subjects consumed an isocaloric meal, high in one
macronutrient: high-protein, high-fat, or high-carbohydrate (Ta-
ble S1). The high-protein diet caused the greatest reduction
in hunger in both normal and obese subjects (Figures 1A and
1B), as previously reported (Latner and Schwartz, 1999; Lejeune
et al., 2006; Porrini et al., 1997). In normal-weight but not obese
subjects, the high-fat meal was more satiating than the high-car-
bohydrate meal. The high-protein meal resulted in the greatest
increment in both total plasma PYY and integrated PYY levels
in both groups, although post-meal levels were lower in obese
subjects (Figures 1C and 1D and Table S2). High-fat meals
caused greater total PYY release than high-carbohydrate meals
in normal but not obese subjects. Satiety and plasma PYY levels
thus varied in parallel.
PYY circulates in both PYY1-36 and PYY3-36 forms, but the
latter has the most potent anorectic effects when administered
peripherally (Chelikani et al., 2005). In fasted normal-weight and
obese subjects, PYY3-36 constitutedw65% of total circulating
PYY, but plasma PYY3-36 concentrations were significantly
lower in the obese group compared with the normal-weight group
(fasting PYY3-36; normal-weight group = 22.7 6 2.2 pmol/l,
obese group = 15.8 6 1.3 pmol/l, p < 0.05). In response to the
different meals, the temporal plasma profiles and integrated
levels of PYY3-36 mirrored those of total PYY in both groups (Fig-
ures 1E and 1F) and varied in parallel with satiety. Neither
plasma-active ghrelin levels nor plasma-active GLP-1 levels
showed differential responses to protein, fat, or carbohydrate
intake (Figures S1A–S1D and Table S2). Leptin levels were
unchanged during the study. The high-carbohydrate diet caused
the greatest release of insulin in both subject groups (Table S2).
These findings suggested that PYY could mediate the satiating
effects of protein in humans. We therefore developed a rodent
experimental model in which to investigate this possibility.
High-protein diets reduce caloric intake and increase
PYY release in mice
High-protein diets have been demonstrated to increase satiety
and reduce food intake in rodents without causing conditioned
taste aversion (Bensaid et al., 2003). We utilized two isocaloric
high-fat diets, either with normal-protein (HFNP) or high-protein
(HFHP), and two isocaloric low-fat diets, with normal-protein
(LFNP) or high-protein (LFHP), for our studies (Table S3). In a ran-
domized four-way crossover study, when fasted C57Bl/6 mice
were re-fed with each of the different diets, increasing the pro-
tein content of both the low-fat and high-fat diets significantly
decreased ad libitum calorie intake (Figure 2A). Furthermore,
the two high-protein diets (HFHP and LFHP) caused greater
PYY release than the two normal-protein diets (Figure 2B and
integrated AUC: HFNP = 157.1 6 6.6 pmol.8 hr, HFHP =
182.2 6 5.2 pmol.8 hr, LFNP = 138 6 6.8 pmol.8 hr, LFHP =
196.26 7.3 pmol.8 hr. LFNP versus LFHP p < 0.001, HFNP ver-
sus HFHP p < 0.01). In contrast, there was no differential effect
of the different meals on the suppression of either active ghrelin224or desacyl ghrelin (Figures S2A and S2B). These findings were
consistent with our human studies validating the use of mice
as a model.
Long-term high-protein diets reduce weight gain
and enhance PYY synthesis and secretion in mice
We next determined the long-term effects of the different mac-
ronutrient diets on adiposity and plasma levels of gut hormones.
Mice were randomized to four groups, each with ad libitum ac-
cess to one of the diets for 16 weeks. In combination with either
high-fat or low-fat, increased dietary protein resulted in signifi-
cantly less weight gain, less white adipose tissue, and lower
plasma leptin levels compared to the corresponding isocaloric
normal-protein diets (Figures 2C, 2D, and S2C). Moreover,
high-protein diets resulted in higher fasting and fed plasma
levels of PYY than the corresponding normal-protein diets and
an equivalent pattern in both colonic and ileal Pyy mRNA ex-
pression (Figures 2E, 2F, and S2D). In contrast, while plasma-
active ghrelin, desacyl ghrelin, and stomach ghrelin mRNA
were lower in the fed state in all groups, no differences between
the high-protein and normal-protein dietary regimens were
observed (Figures S2E and S2F).
In the arcuate hypothalamic nucleus, orexigenic neuropeptide
Y/agouti-related protein (NPY/AgRP) and anorexigenic pro-
opiomelanocortin (POMC) neurons respond to gut hormones
and adiposity signals (Barsh and Schwartz, 2002; Flier, 2004;
Acuna-Goycolea and van den Pol, 2005; Batterham et al.,
2002; Cowley et al., 2003). We therefore determined the effects
of the different diets on hypothalamic mRNA expression of Npy,
Agrp, andPomc. High-protein resulted in enhanced reduction of
hypothalamic Npy and Agrp mRNA in the fasted to fed transition
(Figures 2G and 2H). No difference in hypothalamic Pomc
mRNA levels was seen between the four diets, although appro-
priate alterations in the fasted to fed transition were apparent
(Figure S2G). Together, these results showed that high-protein
diets reduced adiposity, enhanced PYY synthesis and secre-
tion, and caused greater reduction in hypothalamic expression
of Npy and Agrp mRNA. These findings suggested that PYY
could mediate both the satiating effects of protein and the
associated reduction in long-term adiposity.
Deletion of Pyy in mice causes hyperphagia and obesity
To investigate whether PYY plays a primary role in mediating the
satiating effects of protein, we deleted the entire coding region
of Pyy in mice using CreloxP techniques. We did not leave a
selectable marker or an expression cassette in the Pyy locus
and avoided using homology arms that impinged upon the adja-
cent pancreatic polypeptide (Ppy) gene (Figure 3A). We also
Table 1. Baseline characteristics of the normal-weight and obese human subjects
studied
Normal-weight Obese P value
Age (years) 28.4 6 2.6 32.2 6 4.1 > 0.5
BMI (kg/m2) 23.0 6 0.8 37.7 6 2.4 < 0.001
Body fat (%) 15.6 6 1.5 40.4 6 2.9 < 0.001
Leptin (ng/ml) 1.26 6 0.24 17.47 6 1.92 < 0.001
Glucose (mmol/l) 5.26 6 0.19 5.13 6 0.17 > 0.05
Insulin (pmol/l) 25.6 6 3.6 110.5 6 11.2 < 0.001
Blood parameters are for the fasted state. Values represent mean 6 SEM, and
n = 9 for obese group and n = 10 for normal-weight group.CELL METABOLISM : SEPTEMBER 2006
PYY mediates protein-induced satiationFigure 1. Hunger scores and PYY levels in normal-
weight and obese human subjects following high-
protein, high-fat, and high-carbohydrate isocaloric
meals
A and B) Time course of subjective visual analog
scale ratings (mm change from baseline) for hunger
in normal-weight subjects (A) and obese subjects
(B) after ingestion at time 0 of isocaloric meals.
C and D) Time course of plasma PYY levels in nor-
mal-weight subjects (C) and obese subjects (D) after
ingestion at time 0 of isocaloric meals.
E and F)Area under curve (AUC) for PYY3-36 release
in normal-weight subjects (E) and obese subjects (F)
after ingestion at time 0 of isocaloric meals. * p <
0.05, ** p < 0.01, *** p < 0.001. PROT = high-protein;
CHO = high-carbohydrate; FAT = high-fat. All values
represent group mean 6 SEM, n = 10 for normal
weight subjects, and n = 9 for obese subjects.generated mice that retained the Pyy gene flanked by loxP sites
but lacked the neomycin cassette (Pyylox/lox mice).Pyy null mice,
backcrossed four times onto a C57Bl/6 background, had unde-
tectable levels of circulating PYY and colonic Pyy mRNA (Fig-
ure 3F). Importantly, expression of Ppy was normal (Figure 3G).
Pyylox/lox mice on the same genetic background had normal PYY
levels (data not shown). Pyy null mice were hyperphagic, dis-
playing increased daily cumulative food intake and increased
re-feeding in response to an overnight fast (Figures 4A and
4B). From 5 weeks of age, Pyy null mice of both sexes weighed
significantly more than littermates on normal chow and dis-
played increased body size (Figures 4C and 4D and data not
shown). Ten-week-old Pyy null mice on normal chow were
37% 6 5% heavier (n = 16, p < 0.001) than wild-type (wt) litter-
mate controls. MRI scanning revealed a 237% 6 40% increase
in total body fat, with increased internal and subcutaneous fat
(Figures 4E–4G and Figures S3A and S3B). Plasma leptin levels
were also increased relative to control littermates (Figure S3C).
In contrast, Pyylox/lox mice, which like the Pyy null mice retain the
129Sv genomic region around the Pyy locus, but had normalCELL METABOLISM : SEPTEMBER 2006Pyy expression, displayed no body weight or food intake phe-
notypes and were indistinguishable from wt littermates (Fig-
ure S3D and data not shown). These findings strongly suggest
that the obesity phenotype is due to the loss of Pyy and not
due to the presence of an additional obesity gene linked to the
Pyy locus.
The marked obesity phenotype resulting from the deletion of
Pyy suggests that PYY is a physiologically relevant component
of the mechanisms regulating energy homeostasis. We therefore
reasoned thatPyy null mice would be hypersensitive to the acute
effects of PYY3-36 and that long-term PYY3-36 replacement
would reverse the obesity phenotype. Acute dose-response
studies examining feeding responses over 24 hr revealed that
Pyy null mice were markedly hypersensitive to the anorexigenic
effects of exogenous PYY3-36 at all doses examined compared
to wt littermates (Figures 4H–4L). For example, administration
of 1 mg/100 g of body weight of PYY3-36 to Pyy null mice pro-
duced a similar reduction in food intake as 10 mg/100 g of body
weight of PYY3-36 caused in control mice, a 10-fold increase
in sensitivity (Figures 4H–4L).225
A R T I C L EFigure 2. Effect of high-protein diets on food intake,
PYY profiles, body weight, and hypothalamic neuro-
peptide expression in mice
For all panels: high-fat normal-protein (HFNP: blue
symbols), high-fat high-protein (HFHP: green sym-
bols), low-fat normal-protein (LFNP: black symbols),
and low-fat high-protein (LFHP: red symbols).
A) 24 hr caloric intake in 8- to 10-week-old male
C57Bl/6 mice exposed to different composition
diets, n = 30 per diet. All diets are significantly differ-
ent from each other p < 0.01.
B) Plasma PYY profiles in 10-week-old male C57Bl/6
mice after ingestion of different isocaloric meals, n =
6 per diet.
C) Body weight profiles of male C57Bl/6 mice on dif-
ferent diets for 16 weeks, n = 20 per diet.
D) Inguinal fat pad weights in male C57Bl/6 mice
after 16 weeks on different diets, n = 10 per diet.
E) Fasted (fast) and fed plasma PYY levels in male
C57Bl/6 mice after 16 weeks on different diets, n =
10 per diet.
F) Fasted (fast) and fed colonic Pyy mRNA levels in
male C57Bl/6 mice after 16 weeks on different diets,
n = 10 per diet. Pyy mRNA levels are expressed as
relative Tcea1.
G and H) Fasted (fast) and fed hypothalamic Npy
mRNA levels (G) and Agrp mRNA in male C57Bl/6
mice after 16 weeks on different diets, n = 10 per
diet. Npy and Agrp mRNA levels are expressed as
relative Hprt. All values represent group mean 6
SEM.*p < 0.05, **p < 0.01, ***p < 0.001 for HFNP
versus HFHP, #p <0.05, ##p < 0.01 and ###p <
0.001 for LFNP versus LFHP.For the chronic replacement experiments we adopted two
treatment strategies. Since PYY3-36 is normally released epi-
sodically in response to food intake, we first used an intermittent
treatment protocol. Mice were treated once a day before the
dark phase feeding period with 5 mg/100 g of body weight of
PYY3-36, a dose that inhibited cumulative 24 hr food intake in
Pyy null but not control mice (Figures 4K and 4L). In addition,
we implanted mice with osmotic mini-pumps continuously deliv-
ering PYY3-36 at a dose previously demonstrated to cause
weight loss in mice with diet-induced obesity (Pittner et al.,
2004). To assess whether replacement of PYY3-36 could both
prevent weight gain and cause weight loss in markedly obese
mice we used Pyy null mice at two ages: 12-week-old mice,
which were still gaining weight, and 22-week-old mice, with
marked but relatively stable obesity. After 15 days of once daily
PYY3-36 injections, Pyy null mice lost approximately 20% of
their body weight (Figure 5A). In contrast, saline-treated Pyy226null, saline-treated wt mice and PYY3-36-treated wt animals
had stable weight profiles (Figure 5A). Within one week of stop-
ping PYY3-36 replacement Pyy null mice regained more than
60% of the body weight they had lost, demonstrating that the
re-removal of PYY resulted in the reappearance of the obesity
phenotype (weight change in the 7-day period post-study: pre-
viously saline-treated wt mice = 0.996 0.19 g, previously PYY3-
36-treated wt mice = 0.96 6 0.25 g, previously saline-treated
Pyy null mice = 1.54 6 0.27 g, previously PYY3-36-treated
Pyy null mice = 7.89 6 0.4 g, p < 0.001). In the chronic osmotic
mini-pump studies, PYY3-36 treatment for 21 days in 12-week-
old Pyy null mice resulted in weight reduction and the prevention
of the weight gain seen in saline-treated animals of the same ge-
notype, normalizing the body weight of Pyy null mice to that of
saline-treated wt littermates (Figure 5B). This weight loss was
associated with a reduction in inguinal fat pad weight (Figure 5C).
Treatment of obese weight-stable 22-week-old Pyy null miceCELL METABOLISM : SEPTEMBER 2006
PYY mediates protein-induced satiationFigure 3. Targeting of the Pyy locus and lack of PYY peptide in Pyy null mice
A) Targeting construct design, restriction map of the Pyy and Ppy loci, and the Pyy locus after homologous recombination and after deletion of the neomycin cassette and
Pyy-coding region.
B) External probes Pyy-A and Pyy-B were used to distinguish the homologously recombined (HR) from the wild-type (wt) locus after Xho1 digest of ES cell DNA.
C) e-Flp-mediated deletion of the neomycin cassette was confirmed by PCR using primers NeoA and NeoB.
D)Cre-mediated deletion of thePyy-coding region was confirmed using primers D1, D2, and D3. The 326 bp and 370 bp products obtained with D1 and D2 demonstrate the
presence of the wt and floxed Pyy alleles. The 350 bp product indicates the gene deletion (GD) of the Pyy coding region between the loxP sites.
E)Genotyping of thePyy null allele using primers D1, D2, and D3 to identify wt mice with the intactPyy gene (G),Pyy heterozygote (het), and gene-deleted (GD)Pyy null mice.
F) Absence of PYY peptide in the plasma of fed Pyy null mice, n = 8 per genotype.
G) Equivalent pancreatic polypeptide (Ppy) mRNA expression in pancreases from male wt and Pyy null mice, n = 8 per genotype. Data presented are mean 6 SEM.with PYY3-36 resulted in a 24.3% 6 0.5% reduction in body
weight compared to saline-treated Pyy null mice (p < 0.001)
(Figure 5D). Taken together, the acute dose-response studies
demonstrating increased sensitivity of Pyy null mice to exoge-
nous PYY3-36 and the reversal of the obesity phenotype of
Pyy null mice with chronic PYY3-36 treatment strongly suggest
that their phenotype is due to the loss of Pyy, which acts as
a physiologically relevant satiety hormone.
PYY3-36 has been shown to decrease feeding when injected
into the arcuate nucleus, alter expression of hypothalamic NpyCELL METABOLISM : SEPTEMBER 2006and Pomc mRNA (Challis et al., 2003), and have acute electro-
physiological effects on arcuate NPY and POMC neurons
(Acuna-Goycolea and van den Pol, 2005; Batterham et al.,
2002). Therefore, we examined the effects of Pyy deletion on
expression of hypothalamic Npy, Agrp, and Pomc mRNA. Com-
pared to wt littermate controls, Pyy null mice displayed in-
creased levels of Npy mRNA in the fasted state and a failure
to regulate Npy expression upon feeding (Figure 5E). Fasting
levels of Agrp mRNA were similar in Pyy null and wt control
mice but were significantly higher inPyy null mice in the fed state227
A R T I C L EFigure 4. Pyy null mice display hyperphagia and
obesity and have increased sensitivity to exogenous
PYY3-36
A) 24 hr food intake in 8-week-old male wild-type
control (wt) and Pyy null mice on regular chow,
n = 12.
B) 24 hr food intake in 8-week-old male wt and Pyy
null mice in response to 16 hr overnight fast, n = 12.
C) Body weight profiles of male wt (open triangles)
and Pyy null mice (closed circles) on regular chow,
n = 16 (p < 0.05 for all data points).
D) Typical external dorsal appearance of 10-week-
old male wt and Pyy null mice.
E) Percentage body fat in 10-week-old male wt and
Pyy null mice determined by MRI, n = 6.
F) Exposed ventral view of 10-week-old wt and PYY
null mice illustrating increased body fat.
G) Representative cross-sectional MRI scans of
10-week-old male wt and Pyy null mice.
H–L)wt and Pyy null mice were fasted overnight then
injected i.p with saline or PYY3-36 at the doses indi-
cated (mg per 100 g body weight) and cumulative
food intake measured, n = 12 per genotype for
each dose. 8 hr cumulative food intake in wt (I) and
Pyy null mice (J) and 24 hr cumulative food intake
in wt (K) and Pyy null (L) mice. All data presented
are mean 6 SEM. *p < 0.05, **p < 0.01.(Figure 5F). In Pyy null mice there was a trend to lower Pomc
levels in the fed state compared to control animals, but no differ-
ences were observed in fasted mice (Figure S3E). These findings
suggest that PYY regulates hypothalamic neuropeptide expres-
sion, but it remains unclear whether this is a direct effect or also
involves other pathways such as vagal inputs or the brainstem.
Pyy null mice are resistant to the satiating and
weight-reducing effects of high-protein diets
We usedPyy null mice to test the hypothesis that PYY is required
for the satiating and weight-reducing effects of high-protein di-
ets. Using a four-way crossover study design we examined the
effects of the HFNP, HFHP, LFNP, and LFHP diets on 24 hr food
intake inPyy null mice, wt littermate controls, andPyylox/lox mice.
wt littermates and Pyylox/lox mice exhibited a similar feeding re-
sponse to the four different diets to that seen in our experiments
with C57Bl/6 mice, suggesting that genetic background did not
influence this finding (Figures 2A, 6A, and 6B). When dietary pro-
tein was kept constant an increase in the carbohydrate content
and decrease in fat content resulted in equivalent 25% reduc-
tion in caloric intake in Pyy null mice, wt littermate controls,
and Pyylox/lox mice (compare HFNP versus LFNP and HFHP
versus LFHP) (Figures 6A–6C). These results demonstrate that228the food intake response to alterations in dietary fat and carbo-
hydrate do not require PYY. In contrast, while increasing the
protein content of the low-fat (LFHP) and high-fat (HFHP) diets
reduced ad libitum caloric intake in wt controls and Pyylox/lox
mice, the satiating effects of high protein were abolished in
the Pyy null mice (Figures 6A and 6C). Moreover, in Pyy null
mice the weight-reducing effects of the HFHP diet were absent
(Figure 6D). These findings suggest that PYY is required for the
satiating and weight-reducing effects of protein. Mice lacking
Npy2r, which mediates the anorectic effects of peripherally
administered PYY3-36 (Abbott et al., 2005b; Batterham et al.,
2002; Scott et al., 2005), also failed to reduce their calorie intake
in response to increased dietary protein while responding to
changes in dietary fat and carbohydrate under equivalent
protein conditions (Figure 6E).
Discussion
Peripheral administration of PYY3-36 to rodents, primates, and
humans acutely decreases food intake (Batterham et al., 2002,
2003a; Chelikani et al., 2005, 2006; Degen et al., 2005; Koegler
et al., 2005; Scott et al., 2005). Furthermore, chronic administra-
tion of PYY reduces adiposity in rodents (Chelikani et al., 2006;CELL METABOLISM : SEPTEMBER 2006
PYY mediates protein-induced satiationFigure 5. Effect of exogenous PYY3-36 on body
weight in Pyy null mice
A) Effect of once daily i.p PYY3-36 (5 mg/100 g body
weight) or saline on body weight in 20-week-old male
wt and Pyy null mice. Results are expressed as per-
centage change of starting body weight, n = 8 per
treatment group.
B) Effect on body weight of PYY3-36 (50 mg/100 g
body weight/day) or saline administered continu-
ously to 12-week-old male Pyy null or wt mice by
mini-osmotic pump for 21 days, n = 12 per treatment
group.
C) Inguinal fat pad weight after 21 days continuous
treatment with PYY3-36 (50 mg/100 g body weight/
day) or saline in male Pyy null or wt mice, n = 12 (sa-
line v PYY3-36 treated Pyy null mice, ***p < 0.001).
D) Effect on body weight of PYY3-36 (50 mg/100 g
body weight/day) or saline administered continu-
ously to 22-week-old female Pyy null or wt mice by
mini-osmotic pump for 15 days, n = 6 per treatment
group.
E and F) Expression of hypothalamic Npy mRNA (E)
and AgRP mRNA (F) in fasted (fast) and fed condi-
tions in wt and Pyy null mice determined by RT-
PCR. Results are expressed relative to Hprt mRNA,
n =10 per group. All data presented are mean 6
SEM. **p < 0.01 wt fed versus wt fasted, #p < 0.05
Pyy null versus wt.Pittner et al., 2004). Despite these findings, the role of PYY as a
negative regulator of energy homeostasis has been questioned
(Tschop et al., 2004). Here we show thatPyy null mice are hyper-
phagic and develop marked obesity but are hypersensitive to
exogenous PYY. Moreover, chronic treatment with PYY re-
verses their obesity phenotype. These findings provide compel-
ling evidence that PYY is a physiologically relevant regulator of
food intake and body weight.
The phenotype of our Pyy null mouse differs from that of two
recently described models (Boey et al., 2006; Schonhoff et al.,
2005). In contrast to our model, these mice were generated
with gene replacement vector techniques and retain exogenous
genetic material in the Pyy locus. The model of Schonhoff et al.
expresses lacZ from the Pyy start site and also lacks expression
of the pancreatic polypeptide gene (Ppy), which is adjacent to
the Pyy gene. It is unclear why expression of the Ppy gene is dis-
rupted, but one potential reason is that the homologous recom-
bination event has interfered with the regulatory sequences re-
quired for Ppy expression. While pharmacological evidence
has implicated PPY in energy homeostasis, the physiological
role of this hormone is currently unclear (Batterham et al.,
2003b). Combined disruption of Pyy and Ppy may therefore
lead to compensatory changes in the mechanisms regulating
energy homeostasis, making interpretation of the physiological
role of PYY alone impossible in this model. The Pyy null mouseCELL METABOLISM : SEPTEMBER 2006generated by Boey et al. retains both green-fluorescent protein
and Cre recombinase expression cassettes within thePyy locus.
PPY is detectable by immunocytochemistry in this model but it
is unclear if expression levels are normal. The expression of Cre
recombinase within L cells and PYY-producing cells in the pan-
creatic islets may have adverse effects upon these cell types as
recently it has been demonstrated that transgenic mice ex-
pressing Cre recombinase in b cells have defective glucose ho-
meostasis (Lee et al., 2006). Differences in genetic background
may also contribute to the phenotypic discrepancies. To delete
the neomycin cassette, Schonhoff et al. used a deletor mouse
on an FVB background (Schonhoff et al., 2005), which is an obe-
sity-resistant strain when either on a high-fat diet or when carry-
ing a transgene that causes obesity on a C57Bl/6 background
(Chen et al., 2005; Ludwig et al., 2001). Boey et al. utilized
C57Bl/6 mice to generate their model, but the precise genetic
background studied is not stated. In contrast, we have back-
crossed our Pyy null allele onto a C57Bl/6 background for anal-
ysis. Furthermore, we have studied the Pyylox/lox mice that retain
the Pyy locus and normal Pyy expression and have a similar ge-
netic background to our Pyy null mice. Pyylox/lox mice are indis-
tinguishable from wt control littermates, further suggesting that
the phenotype of our mice is not due to genetic background, the
presence of an obesity gene linked to the Pyy locus, or a feature
of our gene-targeting strategy. Our data robustly demonstrating229
A R T I C L EFigure 6. Pyy null mice resist the satiating effects of
protein
For all panels: high-fat normal-protein (HFNP: blue
bar), high-fat high-protein (HFHP: green bar), low-
fat normal-protein (LFNP: black bars), and low-fat
high-protein (LFHP: red bars). Food intake is ex-
pressed as a % of intake of the HFNP diet.
A) 24 hr cumulative food intake of different diets
following an overnight fast in 8-week-old female wt
mice, n = 18 per diet group; all diets are significantly
different from each other, p < 0.05.
B) 24 hr cumulative food intake of different diets in
8-week-old female Pyylox/lox, n = 12 per diet group;
all diets are significantly different from each other,
p < 0.05.
C) Total 24 hr cumulative food intake of different di-
ets following an overnight fast in 8-week-old female
Pyy null mice. n = 17 per group, ** p < 0.01, high-
fat diets versus low-fat diets.
D)Body weight gain in male wt andPyy null mice with
ad libitum access to HFNP or HFHP diets for 8
weeks, n = 8 per group, **p < 0.01, HFNP versus
HFHP.
E) 24 hr cumulative food intake of different diets
following an overnight fast in 8-week-old female
Npy2r null mice, n = 12 per diet group, **p < 0.01
high-fat diets versus low-fat diets. All data presented
are mean 6 SEM.that Pyy deficiency causes obesity that can be reversed by PYY
replacement confirms the physiological role of this hormone in
energy homeostasis.
Our studies revealed that fasting and postprandial levels of
PYY were reduced in the obese subjects compared with the
normal-weight subjects in agreement with previous studies in
obese adults and children (Alvarez Bartolome et al., 2002; Bat-
terham et al., 2003a; Korner et al., 2005; le Roux et al., 2006b;
Roth et al., 2005; Stock et al., 2005). However, not all of these
studies have demonstrated reduced levels in the fasted state
(Korner et al., 2005; Stock et al., 2005). The reasons for this dis-
crepancy have not been determined, but the duration of fasting
before sampling affects plasma PYY concentrations (Chan
et al., 2006). The mechanistic links between PYY and obesity
are likely to be complex. The phenotype of our Pyy null mouse
suggests that primary PYY deficiency causes obesity. In addi-
tion, our studies in mice with diet-induced obesity demonstrate
that the development of obesity reduces PYY synthesis, fasting
PYY levels, and PYY secretion in response to food intake. The230finding that weight reduction in obese children results in in-
creased PYY levels further suggests a reciprocal relationship
between obesity and PYY (Roth et al., 2005).
Interestingly, in our current studies the high-fat meal resulted
in a greater total PYY release than high-carbohydrate meal in the
normal-weight subjects, but this effect was not seen in obese
subjects. This suggests that in obese subjects PYY release in re-
sponse to high-fat diets is attenuated. This observation may re-
flect the fact that we used equivalent caloric loads in normal and
obese humans and therefore a relatively lower kcal/kg of body
weight food intake in the obese subjects, which limits the com-
parisons that can be made between groups. However, recent
studies using a 47% fat content meal have shown that for any
given caloric load between 250 and 3000 kcal, peak plasma
PYY concentrations were less in obese than normal-weight sub-
jects (le Roux et al., 2006b). Indeed it was estimated that the ca-
loric load required to evoke a given PYY response in the obese
subjects was more than double that required in the normal-
weight cohort (Young, 2006). Therefore, despite the limitationsCELL METABOLISM : SEPTEMBER 2006
PYY mediates protein-induced satiationof our studies, it is clear that the obese state is associated in
both rodents and humans with reduced PYY levels in response
to food intake. However, it remains uncertain how the obese
state alters PYY levels, but potential mechanisms include the
presence or absence of circulating factors that suppress or
enhance PYY secretion or other alterations in L cell function
(Young, 2006). In addition, such mechanisms may be specific
to particular macronutrients. Taken together it is therefore likely
that reduced PYY levels could play a dual role in the pathogen-
esis of obesity being both a primary driver while also being
required for the persistence of obesity.
Previous studies have reported increased satiety and reduced
hunger following ingestion of high-protein ‘‘meals.’’ The majority
of these have used liquid pre-loads, varying in caloric intake
(250 kcal to 450 kcal) and protein content (43%–84%), and
then assessed subsequent hunger and/or ad libitum caloric in-
take (Bowen et al., 2006; Latner and Schwartz, 1999; Poppitt
et al., 1998). There is some limited evidence from human studies
that these acute effects on satiety translate into longer-term
benefits. For example, a 6 day intervention study examining
the effects of a normal-protein (15%) low-fat American Heart As-
sociation diet compared with high-protein (31%) low-fat diet
found that ad libitum caloric intake was reduced by 25% with
the increased protein content diet (Dumesnil et al., 2001). In
a randomized 6 month trial comparing ad libitum high-protein
(25%) low-fat diet with a normal-protein (12%) low-fat diet for
6 months, Skov et al. demonstrated improved weight loss and
fat mass loss with enhanced-protein diet, an effect attributed
to reduced food intake (Skov et al., 1999). Furthermore, increas-
ing the protein content of the diet from 15% to 18% during
weight maintenance after weight loss has been shown to halve
the amount of weight regained (Westerterp-Plantenga et al.,
2004). Protein-rich diets caused the greatest satiation in our
acute human and rodents feeding studies and the greatest re-
duction in weight gain in our chronic rodent diet studies, consis-
tent with these published studies on the beneficial effects of
dietary protein.
Our studies aimed at understanding the effects of macronutri-
ents on satiation and body weight in humans demonstrated that
high-protein meals caused the greatest reduction in hunger cou-
pled with greatest increase in PYY compared to fasting levels in
both groups. However, the peak and AUC PYY levels obtained
in the obese group were less than those observed in the nor-
mal-weight group, and this correlated with a smaller reduction
in hunger scores in the obese subjects. In our rodent studies,
long-term exposure to high-protein diets was associated with
elevated Pyy expression and PYY plasma levels and reduced
weight gain. Critically, Pyy null mice in both acute feeding stud-
ies and in long-term dietary manipulation studies were resistant
to the satiating and anti-obesity effects of high-protein diets. In
contrast, altering the fat and carbohydrate content of the diets
while keeping the protein content constant resulted in a similar
change in feeding in C57Bl/6, Pyylox/lox, Pyy null, and their wt lit-
termates, suggesting that deletion of Pyy specifically affects the
satiating effects of protein.
There may be an evolutionary explanation for why protein is
the most satiating of the macronutrients. It has been estimated
that hunter-gatherer diets contained significantly higher protein
content than most modern diets (Cordain et al., 2000). As far as
can be judged, hunter-gatherer societies were largely protected
from the diseases of affluence (Cordain et al., 2000). The readyCELL METABOLISM : SEPTEMBER 2006availability of carbohydrate-rich grains and cereals has been a
recent development in human nutrition with the onset of orga-
nized agriculture. Many of the physiological systems that regu-
late food intake were probably established and may function
better under lower-carbohydrate and higher-protein dietary
conditions. This might explain the effects of protein on satiation
and PYY release and the marked phenotype caused by the
deletion of the Pyy gene.
Bariatric surgery, a highly effective but invasive means of in-
ducing weight loss, is associated with elevated PYY levels,
which may underlie the weight-reducing effects of this proce-
dure (Korner et al., 2005; le Roux et al., 2006a; Morinigo et al.,
2006). However, the mechanisms by which such surgical inter-
ventions alter gut hormone profiles are unknown. Indeed, little
is known about the mechanism by which nutrients normally
stimulate gut hormone release. Increasing PYY release to en-
hance the satiating effects of meals, perhaps by harnessing
endogenous physiological systems, is an attractive therapeutic
option for obesity. Strategies could include enhancing meal pro-
tein content within healthy limits or the development of protein-
mimetics. In summary, our current studies have established the
physiological role of PYY as a regulator of energy homeostasis
and demonstrated that it mediates the satiating and weight-
reducing effects of dietary protein.
Experimental procedures
Human studies
Ten healthy normal-weight and ten obese male volunteers were recruited by
advertisement. Exclusion criteria were the use of medications and presence
of any medical or psychiatric illnesses or food allergies. Subject characteris-
tics are presented in Table 1. All subjects gave written informed consent for
the study, and approval was obtained from the University College London
(UCL) research ethics committee. A randomized three-way crossover study
was performed, with each subject being studied on three separate occasions
at weekly intervals. One obese subject dropped out due to an unrelated
illness. On the day prior to each test meal, subjects consumed a similar
meal between 1900 hr and 2000 hr and then fasted and drank only water. Af-
ter arrival at the investigation center at 1000 hr, a cannula was inserted into
an ante-cubital arm vein and subjects relaxed for 30 min before the start of
the study protocol. Subjects completed validated visual analog scale (VAS)
questionnaires to assess hunger (Flint et al., 2000). Blood samples were
taken and VAS assessed at baseline, immediately before the meal, and
then at 30 min intervals until 3 hr post-meal. On each attendance at time
zero, subjects were given the test meals, in random order, and instructed
to finish this within a 25 min period. Isocaloric high-protein, high-fat, and
high-carbohydrate test meals were studied (Table S1). For further details of
the test meals and assays used see Supplemental Data.
Mouse studies
Mice were maintained on a 12 hr light/dark cycle (lights on at 0700 hr) under
constant temperature with free access to water and standard mouse chow
(Teklad Global 2018) and housed in specific-pathogen free facilities. All in
vivo studies were performed in accordance to the Home Office Animal Pro-
cedures Act (1986) and London, UK, and UCL, UK ethical guidelines. C57Bl/6
mice were purchased at 6 weeks of age from Charles River UK Ltd (Margate,
Kent, United Kingdom). Food and mouse weights were measured using
a Sartorius BP610 balance. High-fat normal-protein (HFNP), high-fat high-
protein (HFHP), low-fat normal-protein (LFNP), and low-fat high-protein
(LFHP) diets were purchased from Research Diets (Research Diets Inc.,
New Brunswick New Jersey). All four diets were marked with different taste-
less food coloring and their composition is presented in Table S3.
Targeting of the mouse Pyy gene
Pyy null mice were generated using standard CreloxP technology (see Sup-
plemental Data).231
A R T I C L EDietary studies in mice
For the diet studies, 6-week-old male C57Bl/6, Pyy null mice, Pyylox/lox mice,
and Npy2r null mice and wt littermate controls were singly housed. To allow
acclimatization to the study protocol, mice were fasted and re-fed each of the
different diets (HFNP, HFHP, LFNP, LFHP) on four different occasions, in
a random order. Mice from each genotype were then divided into four
weight-matched groups and underwent a randomized four-way crossover
study. On each study day mice were fasted overnight for 14 hr and then
re-fed with one of the 4 different diets and ad libitum food intake measured.
For gut hormone release studies, mice were habituated to eat 4 kcal of each
of the different diets in a 1 hr period after an overnight fast. Mice were ran-
domized into HFNP, HFHP, LFNP, and LFHP groups and were culled at 1,
2, 4, 6, and 8 hr post-re-feed. For long-term diet studies, four groups of
mice were allowed ad libitum access to one of the four diets for 16 weeks.
Mice were weighed weekly and culled either after an overnight fast or in
the fed state. For details of tissue harvesting and assays used refer to
Supplemental Data.
PYY3-36 replacement studies
Pyy null mice and wt littermates were singly housed and acclimatized to sa-
line intra-peritoneal (i.p.) injections and to a fasting and re-feed protocol.
Each genotype was then randomized into groups, fasted overnight, and
then injected i.p with saline or PYY3-36 (at doses indicated in the figure leg-
ends) at 0800 hr and food re-weighed at 1, 2, 4, 6, 8, and 24 hr post-injection.
For chronic i.p. injection studies, Pyy null and control mice were acclimatized
to being singly housed and to i.p. injections prior to being randomized to
PYY3-36 treatment or saline. Mice received a single i.p. injection of PYY3-
36 (5 mg/100 g body weight) or saline at the beginning of the dark-phase feed-
ing period for 14 days and body weight was monitored daily. For the contin-
uous infusion studies, Alzet osmotic pumps (model 2004, Charles River UK
Ltd) were loaded with phosphate-buffered saline (PBS) or PYY3-36 dissolved
in PBS so as to deliver 500 mg/kg/day. After 48 hr incubation in sterile PBS at
37C to initiate delivery, pumps were implanted subcutaneously between the
scapulae in mice anaesthetized with isoflurane. Wounds were closed with
surgical staples. Food intake and body weight were subsequently monitored
every 24 hr in the early light phase for 3 weeks. At the end of the study mice
were terminally anaesthetized and inguinal fat pads were dissected and
weighed.
Statistics
For all studies, results are expressed as mean 6 SEM. Values for integrated
area under the curve (AUC) hormone concentrations versus time were calcu-
lated above zero concentration by using the trapezoid rule. Within-subject
comparisons were made using repeated-measures analysis of variance
(ANOVA) with Newman Keul’s post-hoc tests. Comparisons between normal
weight and obese groups were made using nonpaired Student’s t test.
Significance was set at p < 0.05.
Supplemental data
Supplemental data include additional experimental procedures, three tables,
and three figures and can be found with this article online at http://www.
cellmetabolism.org/cgi/content/full/4/3/223/DC1/.
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